Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9630205rdf:typepubmed:Citationlld:pubmed
pubmed-article:9630205lifeskim:mentionsumls-concept:C0023493lld:lifeskim
pubmed-article:9630205lifeskim:mentionsumls-concept:C0092801lld:lifeskim
pubmed-article:9630205lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:9630205pubmed:issue4lld:pubmed
pubmed-article:9630205pubmed:dateCreated1998-8-18lld:pubmed
pubmed-article:9630205pubmed:abstractTextAdult T-cell leukemia-lymphoma (ATL) is resistant to currently available chemotherapy and has a poor prognosis. We describe here a patient with ATL successfully treated with 2-chlorodeoxyadenosine (2-CdA). A 75-year-old Japanese male with an acute type of ATL, who had become resistant to the initial cytotoxic chemotherapy, was treated with 2-CdA administered by continuous drip infusion of 0.09 mg/kg/d for seven consecutive days in one month (one cycle). After three cycles of treatment, partial remission (PR) was achieved. Surprisingly, 249 days after the administration of 2-CdA, ATL cells completely disappeared from the peripheral blood. PR was maintained during 10 weeks until evidence of a new lymphadenopathy. No remarkable toxicity of 2-CdA occurred.lld:pubmed
pubmed-article:9630205pubmed:languageenglld:pubmed
pubmed-article:9630205pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9630205pubmed:citationSubsetIMlld:pubmed
pubmed-article:9630205pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9630205pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9630205pubmed:statusMEDLINElld:pubmed
pubmed-article:9630205pubmed:monthAprlld:pubmed
pubmed-article:9630205pubmed:issn0918-2918lld:pubmed
pubmed-article:9630205pubmed:authorpubmed-author:ChocOOlld:pubmed
pubmed-article:9630205pubmed:authorpubmed-author:GotoTTlld:pubmed
pubmed-article:9630205pubmed:authorpubmed-author:KozuruMMlld:pubmed
pubmed-article:9630205pubmed:authorpubmed-author:TokoroAAlld:pubmed
pubmed-article:9630205pubmed:authorpubmed-author:TobinaiKKlld:pubmed
pubmed-article:9630205pubmed:authorpubmed-author:YufuYYlld:pubmed
pubmed-article:9630205pubmed:authorpubmed-author:UikeNNlld:pubmed
pubmed-article:9630205pubmed:issnTypePrintlld:pubmed
pubmed-article:9630205pubmed:volume37lld:pubmed
pubmed-article:9630205pubmed:ownerNLMlld:pubmed
pubmed-article:9630205pubmed:authorsCompleteYlld:pubmed
pubmed-article:9630205pubmed:pagination411-3lld:pubmed
pubmed-article:9630205pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:9630205pubmed:meshHeadingpubmed-meshheading:9630205-...lld:pubmed
pubmed-article:9630205pubmed:meshHeadingpubmed-meshheading:9630205-...lld:pubmed
pubmed-article:9630205pubmed:meshHeadingpubmed-meshheading:9630205-...lld:pubmed
pubmed-article:9630205pubmed:meshHeadingpubmed-meshheading:9630205-...lld:pubmed
pubmed-article:9630205pubmed:meshHeadingpubmed-meshheading:9630205-...lld:pubmed
pubmed-article:9630205pubmed:meshHeadingpubmed-meshheading:9630205-...lld:pubmed
pubmed-article:9630205pubmed:meshHeadingpubmed-meshheading:9630205-...lld:pubmed
pubmed-article:9630205pubmed:meshHeadingpubmed-meshheading:9630205-...lld:pubmed
pubmed-article:9630205pubmed:meshHeadingpubmed-meshheading:9630205-...lld:pubmed
pubmed-article:9630205pubmed:year1998lld:pubmed
pubmed-article:9630205pubmed:articleTitleAdult T-cell leukemia-lymphoma successfully treated with 2-chlorodeoxyadenosine.lld:pubmed
pubmed-article:9630205pubmed:affiliationDepartment of Hematology, National Kyushu Cancer Center, Fukuoka.lld:pubmed
pubmed-article:9630205pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9630205pubmed:publicationTypeCase Reportslld:pubmed
pubmed-article:9630205pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9630205lld:pubmed